Pnd2 - Risk of Parkinson’s Disease (Pd) in Patients Taking Adrenergic Drug Treatments

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1969
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Freezing of Gait in Parkinson’s Disease: Pathophysiology, Risk Factors and Treatments

Translational Neurodegeneration
Molecular NeuroscienceNeurologyCellularCognitive Neuroscience
2020English

Drug Repurposing in Parkinson’s Disease

CNS Drugs
PsychiatryMental HealthNeurologyPharmacology
2018English

G-Force PD: A Global Initiative in Coordinating Stem Cell-Based Dopamine Treatments for Parkinson’s Disease

npj Parkinson's Disease
2015English

Dopaminergic Influences on Risk Preferences of Parkinson’s Disease Patients

Cognitive, Affective and Behavioral Neuroscience
Behavioral NeuroscienceCognitive Neuroscience
2018English

Vocal Changed in Parkinson’s Disease Patients

Archives of Biomedical and Clinical Research
2019English

Fatigue in Patients With Parkinson’s Disease

Behavioural Neurology
MedicineNeurologyPhysiological PsychologyNeuropsychology
2000English

Gout and the Risk of Parkinson’s Disease in Denmark

European Journal of Epidemiology
Epidemiology
2013English

Prevalence of Depression in Parkinson’s Disease Patients in Ethiopia

Journal of Clinical Movement Disorders
2014English

Premorbid Personality and the Risk of Parkinson’s Disease

Journal of Neurology Research
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy